EUROSTAD
Research type
Research Study
Full title
European Prospective Observational Study in Patients Eligible for Systemic Immunosuppressive Therapy for Atopic Dermatitis (AD)
IRAS ID
211871
Contact name
Michael Cork
Contact email
Sponsor organisation
Sanofi Aventis Groupe
Eudract number
2016-000629-38
Clinicaltrials.gov Identifier
DERM 31348, NIHR
Duration of Study in the UK
2 years, 9 months, 1 days
Research summary
Eurostad is an observational study aiming to collect information about the treatment of patients with atopic dermatitis.
This will be done by gathering information on patient's prior treatment and then gathering information on their ongoing treatment of atopic dermatitis over 18 months. The study will also gather information on the patient's quality of life through a number of questionnaires, completed either at routine hospital visits or at home. As this is an observational study there is no investigational product administered as part of the study and the patient's treatment will be decided by their treating physician.
REC name
North West - Haydock Research Ethics Committee
REC reference
17/NW/0164
Date of REC Opinion
14 Mar 2017
REC opinion
Favourable Opinion